- Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer
[作者:Gradishar, WJ; Krasnojon, D; Cheporov, S; Makhson, AN; Manikhas, GM; Clawson, A; Bhar, P,期刊:Journal of clinical oncology, 页码:3611-3619 , 文章类型: Article,,卷期:2009年27-22]
- PurposeIn patients with metastatic breast cancer (MBC), nab-paclitaxel produced significantly higher antitumor activity compared with patients who received solvent-based paclitaxel. This phase II study examined the antit...
- Menstrual Cycle and Surgical Treatment of Breast Cancer: Findings From the NCCTG N9431 Study
[作者:Grant, CS; Ingle, JN; Suman, VJ; Dumesic, DA; Wickerham, DL; Gelber, RD; Flynn, PJ; Weir, LM; Intra, M; Jones, WO; Perez, EA; Hartmann, LC,期刊:Journal of clinical oncology, 页码:3620-3626 , 文章类型: Article,,卷期:2009年27-22]
- PurposeFor nearly two decades, multiple retrospective reports, small prospective studies, and meta-analyses have arrived at conflicting results regarding the value of timing surgical intervention for breast cancer on the...
- Insurance Status, Comorbidity Level, and Survival Among Colorectal Cancer Patients Age 18 to 64 Years in the National Cancer Data Base From 2003 to 2005
[作者:Robbins, AS; Pavluck, AL; Fedewa, SA; Chen, AY; Ward, EM,期刊:Journal of clinical oncology, 页码:3627-3633 , 文章类型: Article,,卷期:2009年27-22]
- PurposePrevious analyses have found that insurance status is a strong predictor of survival among patients with colorectal cancer aged 18 to 64 years. We investigated whether differences in comorbidity level may account ...
- Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: Analysis of Graft Sources and Long-Term Outcome
[作者:Tomblyn, MB; Arora, M; Baker, KS; Blazar, BR; Brunstein, CG; Burns, LJ; DeFor, TE; Dusenbery, KE; Kaufman, DS; Kersey, JH; MacMillan, ML; McGlave, PB; Miller, JS; Orchard, PJ; Slungaard, A; Tomblyn, MR; Vercellotti, GM; Verneris, MR; Wagner, JE; Weisdorf, DJ,期刊:Journal of clinical oncology, 页码:3634-3641 , 文章类型: Article,,卷期:2009年27-22]
- PurposeAnalysis of hematopoietic cell transplantation (HCT) for high-risk or recurrent acute lymphoblastic leukemia (ALL) using different donor sources is confounded by variable conditioning and supportive care.Patients ...
- Predictors of Primary Imatinib Resistance in Chronic Myelogenous Leukemia Are Distinct From Those in Secondary Imatinib Resistance
[作者:Zhang, WW; Cortes, JE; Yao, H; Zhang, L; Reddy, NG; Jabbour, E; Kantarjian, HM; Jones, D,期刊:Journal of clinical oncology, 页码:3642-3649 , 文章类型: Article,,卷期:2009年27-22]
- Purpose A subset of patients with chronic myelogenous leukemia (CML) do not respond to the tyrosine kinase inhibitor (TKI) imatinib mesylate. Such primary imatinib resistance is distinguished from secondary resistance wh...
|